Director, Statistical Programming

About Alnylam

Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by “interfering” with mRNA that cause or contribute to disease.

Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients.

Provides statistical programming leadership and guidance for early/late phase studies across a compound and/or complex clinical development program(s). He/she is responsible for overseeing all statistical programming activities across a compound, including technical and project leadership overseeing the quality and timely delivery of all statistical programming deliverables for studies and/or for worldwide regulatory submissions. He/she ensures the team develops, maintains, validates and runs quality SAS programs that access, visualize, analyze, and report clinical trial data in accordance with statistical analysis plans, ICH guidelines, and applicable regulatory requirements.

He/she leads process, technology or standard initiatives that add efficiencies and capabilities to the Statistical Programming and/or Data Sciences, Statistics, and Epidemiology (DSSE) department. He/she directs and partners with Statistical Programming vendors to support all programming activities and priorities.

This is a hybrid position for us and the successful candidate will be required to work from our offices in Maidenhead in line with our global policy.

• Leads statistical programming teams/activities for complex clinical development Compound(s), including worldwide regulatory submissions. Represents Statistical Programming as part of Clinical Trial Working Groups (CTWG), Clinical Development Teams, and/or Clinical Filing teams, and acts as a key decision-maker with biostatistics and data management on DSSE’ analysis/dataset and electronic submission strategies;
• Plans optimal programming and data/analysis review tasks and team member assignments, coordinates and leads programming team delivery/forums;
  Revisits and aligns staffing plans and programming assignments seamlessly as priorities shift;
• Drives analysis dataset/submission flow with Biostatistics, working closely on the development and review/validation of Statistical plans/shells, CDISC SDTM and ADaM specifications and datasets, TLFs and electronic submissions;
• Drives clinical data review and validation flow with Data Management including the development and review of DM documentation (i.e., Data Review Plans, Data Transfer Agreements, etc.), CDISC SDTM specifications, datasets, P21 reporting, and SDTM Reviewer Guides and define packages;
• Coordinates delivery of PV outputs to Drug Safety to support timely Safety…